Prof. Jeff Evans gives a concise summary of the results of the REFLECT study, a non-inferiority study comparing LENVIMA® (lenvatinib) and sorafenib in patients with unresectable hepatocellular carcinoma (HCC). Overall survival was the primary endpoint, for which the criteris for non-inferiority was met. Prof. Evans also discusses the secondary endpoints and safety results of this study and reflects on what these results mean for prescribing in advanced HCC.
This video was recorded in March 2020. Since then the combination of atezolizumab and bevacizumab has been licensed.
LENVIMA® 4mg hard capsules Summary of Product Characteristics
UK-LENA-23-00098 Date of preparation March 2023